CAR-T therapy
| 3 min read
Analysis of two pivotal Yescarta clinical trials revealed that patients' germline DNA influences both toxicity risk and CAR T expansion, opening new opportunities for smarter cell therapy design.
| 4 min read
Positive results for GLP-1 drugs in alcohol use disorder, a new collaboration to advance in vivo CAR T therapies, Phase 3 readouts in oncology, rare disease, and vitiligo, and more led the news this week.
| 6 min read
As deep B cell depletion moves into autoimmune disease, antibody-directed allogeneic NK cell therapy may offer a different path to potency, scalability, and outpatient treatment.
| 3 min read
Researchers showed that an oral medication can activate worn-out T cells.
| 6 min read
As soaring costs and logistical complexity strain traditional cell therapy models, in vivo CAR T is prompting a fundamental rethink of how advanced therapies are manufactured and scaled.
| 4 min read
Living drugs are blurring the line between therapy and biology, challenging decades of assumptions about how medicines are made and controlled.
| 4 min read
Executive orders, AI drug discovery models, pharmaceutical deals, and more led the news this week.
| 4 min read
Marriage linked to lower cancer risk, pharma deals, and more led the news this week.
| 3 min read
A first-of-its-kind CAR T treatment helped a woman achieve year-long remission from three severe autoimmune diseases that resisted nine prior therapies.
| 4 min read
At the Advanced Therapies conference, industry leaders showcased how in vivo CAR T cell and gene delivery innovations could transform accessibility and clinical outcomes.
